Gene Therapy for Cancer

Por Schepelmann, S, Springer, C J
Publicado em 2008

A novel protocol for the one-pot borylation/Suzuki reaction provides easy access to hinge-binding groups for kinase inhibitors

Por Hooper, A., Zambon, A., Springer, C. J.
Publicado no Org Biomol Chem (2016)

Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation.

Por Mason, C S, Springer, C J, Cooper, R G, Superti-Furga, G, Marshall, C J, Marais, R
Publicado em 1999

Gastric enterochromaffin-like (ECL) cells in hypergastrinaemic duodenal ulcer disease.

Por Coupe, M, Rees, H, Springer, C J, Bishop, A E, Morris, J A, Polak, J M, Calam, J
Publicado em 1990

A cytotoxic agent can be generated selectively at cancer sites.

Por Bagshawe, K. D., Springer, C. J., Searle, F., Antoniw, P., Sharma, S. K., Melton, R. G., Sherwood, R. F.
Publicado em 1988

Disposition of the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice.

Por Antoniw, P., Springer, C. J., Bagshawe, K. D., Searle, F., Melton, R. G., Rogers, G. T., Burke, P. J., Sherwood, R. F.
Publicado em 1990

Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs.

Por Blakey, D. C., Davies, D. H., Dowell, R. I., East, S. J., Burke, P. J., Sharma, S. K., Springer, C. J., Mauger, A. B., Melton, R. G.
Publicado em 1995

A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs

Por Spooner, R A, Friedlos, F, Maycroft, K, Stribbling, S M, Roussel, J, Brueggen, J, Stolz, B, O'Reilly, T, Wood, J, Matter, A, Marais, R, Springer, C J
Publicado em 2003